Cholesterol values are poor markers of disease risk in a chronic disease population

Clinical Lipidology

Volumn 4, Issue 5, 2009, Pages 545-551

  Bowden, Rodney G ^a   Griggs, Jackson ^b   Wilson, Ronald L ^c   Gentile, Mindy ^d  

^a BAYLOR UNIVERSITY   (United States)

^b Family Health Center   (United States)

^c Central Texas Nephrology Associates   (United States)

^d GENZYME CORPORATION   (United States)

Author keywords

Albumin; End stage renal disease; HDL C; LDL C; LDL C concentration; Reverse epidemiology

Indexed keywords

ALBUMIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHRONIC DISEASE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; EPIDEMIOLOGICAL DATA; FEMALE; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; NUTRITIONAL STATUS; OUTCOME ASSESSMENT; PARTICLE SIZE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 77649137227     PISSN: 17460875     EISSN: None     Source Type: Journal    
DOI: 10.2217/clp.09.56     Document Type: Article

References (25)

1. Diepeveen SHA, Wetzels JFM, Bilo HJG, van Tits LGH, Stalenhoef AFH: Cholesterol in end-stage renal disease: the good, the bad or the ugly? Netherlands J. Med. 66(2), 51-63 (2008).
2. Trivedi H, Xiang Q, Klein JP: Risk factors for non-fatal myocardial infarction and cardiac death in incident dialysis patients. Nephrol. Dial. Transplant 24, 258-266 (2009).
3. Chmielewski M, Carrero JJ, Nordfors L, Lindholm B, Stenvinkel P: Lipid disorders in chronic kidney disease: reverse epidemiology and therapeutic approach. J. Neph. 21, 635-644 (2008).
4. Horwich TB, Fonarow GC: Reverse epidemiology beyond dialysis patients: chronic heart failure, geriatrics, rheumatoid arthritis, COPD, and AIDS. Sem. Dial. 20(6), 549-553 (2007).
5. Marcovecchio ML, Dalton RN, Prevost AT et al.: Prevalence of abnormal lipid profiles and the relationship with the development of microalbuminuria in adolescents with Type I diabetes. Diabetes Care 32, 658-663 (2009).
6. Kalantar-Zadeh K, Kopple JD, Kilpatrick RD et al.: Association of morbid obesity and weight change over time with cardiovascular survival in hemodialysis population. Am. J. Kid. Dis. 46(3), 489-500 (2005).
7. Levin NW, Handelman GJ, Coresh J, Port FK, Kaysen GA: Reverse epidemiology: a confusing, confounding, and inaccurate term. Sem Dial. 20(6), 586-592 (2007).
8. Balakrishnan VS, Rao M: Genetics and reverse epidemiology among patients on chronic hemodialysis. Sem Dial. 20(6), 570-576 (2007).
9. Chavalitdhamrong D, Danovitch GM, Bunnapradist S: Is there a reversal of reverse epidemiology in renal transplant recipients? Sem. Dial. 20(6), 544-548 (2007).
10. Suliman M, Stenvinkel M, Qureshi AR: The reverse epidemiology of plasma total homocysteine as a mortality risk factor is related to the impact of wasting and inflammation. Nephrol. Dial. Transplant. 22, 209-217 (2007).
11. Kalantar-Zadeh K, Block G, Humphreys MH, MCallister CJ, Kopple JD: A low, rather than a high, total plasma homocysteine is an indicator of poor outcome in hemodialysis patients. J. Am. Soc. Nephrol. 15, 442-453 (2004).
12. Nurmohamed SA, Nubé MJ: Reverse epidemiology: paradoxical observations in haemodialysis patients. Netherlands J. Med. 63(10), 376-381 (2005).
13. Kalantar-Zadeh K, Kopple JD: Obesity paradox in patients on maintenance dialysis. Nephrology 151, 57-69 (2006).
14. Power A, Duncan N, Goodlad C: Advances and innovations in dialysis in the 21st Century. Postgrad. Med. J. 85(1000), 102-107 (2009).
15. Kalantar-Zadeh K: Recent advances in understanding the malnutrition- inflammation cachexia syndrome in chronic kidney disease patients: what is next? Sem Dail. 18(5), 365-369 (2005).
16. Cano NJM, Miolane-Debouit Leger J, Heng AE: Assessment of body protein: energy status in chronic kidney disease. Sem. Neph. 29(1), 59-66 (2009).
17. Liu Y, Coresh J, Eustace J et al.: Association between cholesterol level and mortality in dialysis patients role of inflammation and malnutrition. JAMA 291(4), 451-459 (2004). (Pubitemid 38129749)
18. Bowden RG, Hebert S, Wilson R et al.: Comparison of lipid measures and risk stratification among end-stage renal disease patients. J. Neph. 21, 212-218 (2007).
19. Bowden RG, Hebert S, Wilson et al.: A cholesterol primer for health professionals. Californian J. Health Promot. 4, 12-21 (2006).
20. Tulenko TN, Sumner AE: The physiology of lipoproteins. J. Nucl. Cardiol. 9, 638-649 (2002).
21. Kopple JD: The phenomenon of altered risk factor patterns or reverse epidemiology in persons with advanced chronic kidney failure. Am. J. Clin. Nutr. 81, 1257-1266 (2005).
22. Hsu C-Y, McCulloch CE, Iribarren C, Darbinian J, Go AS: Body mass index and risk for end-stage renal disease. Ann. Intern. Med. 144, 21-28 (2006).
23. Wetmore JB, Shireman TI: The ABCs of cardioprotection in dialysis patients: a systematic review. Am. J. Kidney Dis. 53(3), 457-466 (2009).
24. Rambod M, Bross R, Zitterkoph J: Association of malnutrition-inflammation score with quality of life and mortality in hemodialysis patients: a 5-year prospective cohort study. Am. J. Kidney Dis. 53(2), 298-309 (2009).
25. Sorensen VR, Mathiesen ER, Heaf J, Feldt-Rasmussen B: Improved survival rate in patients with diabetes and end-stage-renal disease in Denmark. Diabetologia 50(5), 922-929 (2007).